Note: Descriptions are shown in the official language in which they were submitted.
CA 02341814 2001-03-22
Title: CONTROLLED DELIVERY SYSTEM OF ANTIFUNGAL AND
KERATOLYTIC AGENTS FOR LOCAL TREATMENT OF FUNGAL
INFECTIONS OF THE NAIL AND SURROUNDING TISSUES
FIELD OF THE INVENTION
The present invention relates to a sustained release composition in the
form of varnish or spray comprising an antifungal agent, a keratolytic agent,
or
preferably a combination of antifungal and keratolytic agents, for local
treatment of fungal infections of the nails and/or surrounding tissues. The
composition additionally features a humectant, water, one or more
film-forming polymers, and solvents. The composition may further comprise an
antibacterial agent, an antiviral agent, an antipsoriatic agent or a
combination
thereof.
CA 02341814 2001-03-22
BACKGROUND OF THE INVENTION
Fungal infections are probably the most common disorder of nails
encountered in medical practice. It has been estimated that approximately 90%
of elderly people have some degree of toenail involvement with fungi.
Conditions of moisture and occlusion of the lower extremities favor fungal
colonization. Pain may result from extreme deformity of the nail plate, but
usually, the complaint is one of cosmetic appearance. The most common
organisms involved in the fungal infections of the nail are Trichophyton
rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, Candida
albicans, Microsporum persiccolor, Cephalosporium species, Aspergillus
species, and Fusarium oxysporum.
Fingernail infection is of far greater importance cosmetically and
fortunately clears faster than toenail infection because of the more rapid
growth
rate of fingernails. Despite this, 4-6 months of oral griseofulvin may be
required to bring about complete clearing of the fingernail. For toenail
infections with extensive involvement of multiple digits, withholding
treatment
may be the best decision. One of the factors in the treatment decision is
whether the patient is taking other medications, as griseofulvin interacts
with
several drugs, including anticoagulants.
CA 02341814 2001-03-22
Griseofulvin was the drug of choice for many years, but its low cure rate
and the development of newer, more effective drugs has caused it to lose
favor.
Current therapeutic alternatives include itraconazole and terbinafine. These
drugs are well tolerated, but attention to drug interactions is still
necessary
[Trepanier, E.F and Amsden, G.W. Annals of PJzarmacotherapy, 32, 1998,
204-214].
At present, topical treatment of fungal infections directly to the nail plate
is discouraging. Creams or solutions containing antifungal agents, such as
imidazole derivatives, are able to deliver the active agent to the nail only
for a
short period of time and their permeability/penetration through the nail is
very
low.
U.S. Patent No. 5,120,530 discloses an antimycotically-active nail
varnish, containing an antimycotically-active substance (a morpholine
derivative) and a water-insoluble film former which is a copolymerizate of
acrylic acid esters and methacrylic acid esters having a low content of
quaternary ammonium groups. The formulations disclosed are expected to be
poorly effective because they do not contain a keratolytic agent or a
humectant.
As a result, the nail permeability and consequently the penetration of the
antimycotic agent will be very low. In the present invention the humectant
CA 02341814 2001-03-22
4
entraps the water in the film after evaporatiori of the organic solvents, thus
enabling the solubilization of the active agents in the film. Because the
water
content of the nail is very low, the presence of water in the film should
hydrate
the nail and improve the transport of the active agents into the nail. The
keratolytic agent should also help by increasing the penetration of the
antifungal agent into the deeper layers of the nail.
U.S. Patent No. 4,957,730 discloses a nail varnish comprising a
water-insoluble film-forming substance and an antimycotic substance,
specifically 1-hydroxy-2-pyridones. The formulations disclosed do not contain
to a humectant. The nail permeability of the formulations disclosed and
consequently the penetration of the active agent into the deeper layers of the
nail is expected to be very low, thereby failing to achieve the desired
pharmacological action and cure.
U.S. Patent No. 5,814,305 discloses a nail preparation comprising an
antifungal agent, at least one hydrophilic penetration agent, and a water-
alcohol
solvent medium. The formulations disclosed are disadvantageous; they are in
the form of a lotion or fluid gel and do not contain a film-forming agent. As
a
result a sustained release action is not achieved with these formulations. The
formulations disclosed are disadvantageous since such a dosage form would
CA 02341814 2001-03-22
J
require multiple applications of the fonnulation, leading to poor patient
compliance. Because of the hydrophilic character of the formulations, in the
presence of water or mechanical contact, the lotion or gel will likely be
washed
off or removed from the nail, thereby reducing the accumulation of the active
agents in the nail.
UK Patent Appl. No GB2202743 A discloses a topical antifungal
composition in the form of a lotion, gel or varnish, comprising at least 1% by
weight (relative to the total weight of the composition) of miconazole nitrate
or
econazole nitrate dissolved in a mixture of water, urea, and a water-soluble
to dissolving intermediary. Urea is used in the formulation as a solubility
increasing agent. When the composition is in the form of a varnish it contains
a
resin. The lotion and gel formulations disclosed are disadvantageous since
such
a dosage form will not provide sustained release action and would require
multiple applications of the formulation, leading to poor patient compliance.
Because of the hydrophilic properties of the formulations, in the presence of
water or mechanical contact, the lotion or gel will likely be washed off or
removed from the nail, thereby reducing the accumulation of the active agents
in the nail. The varnish formulations disclosed are disadvantageous, and do
not
contain a humectant. As a result, the antifungal agent will not be solubilized
in
CA 02341814 2001-03-22
6
the film, and the hydration of the nail and transport of the antifungal agent
through the nail will be very low, preventing achievement of the desired
pharmacological action. In addition, UK Patent Appl. No GB2202743 A
describes a delivery system specific for miconazole nitrate or econazole
nitrate,
which is not therefore a general delivery system for other antifungal agents.
None of these prior art references suggest or disclose the use of a
combination of antifungal agent, keratolytic agent, and a humectant (glycerol
at
high concentrations). This combination is particularly advantageous because it
increases the penetration of the active antifungal agent through the nail and
io thus provides better pharmacological action.
U.S. Patent No. 5,346,692 discloses a nail lacquer for treating
onychomycosis, which comprises (a) a film former agent, (b) at least one
antimycotically active substance, (c) urea; and (d) a solvent which comprises
(i) 50-70 wt. % of acetone; and (ii) 30-50 wt. % of 90 volume % aqueous
ethanol. The formulations disclosed are disadvantageous since they use high
concentrations of the antimycotically active substance and urea, thereby
causing unwanted adverse effects (for example irritation and burning) which
leads to poor compliance.
The formulations disclosed do not contain glycerol which would entrap
CA 02341814 2001-03-22
7
the water in the film after evaporation of the organic solvents. The presence
of
water in the film enables the active agents to be maintained in a soluble form
that is readily available for pharmacological action. Since the water content
in
the nail is very low, the presence of water in the film hydrates the nail so
that
the active agents can be delivered into deeper layers of the nail.
There is thus a need for, and it would be useful to have, a better
formulation, containing low concentrations of the antifungal and keratolytic
agents, to deliver pharmacologically active agents to the nail for the
treatment
of fungal infection thereof. This formulation would feature a film-forming
agent and a humectant preferably glycerol, for trapping water in the film
formed on the nail, and the water so trapped would hydrate the nail for
delivery
of the agent thereto.
This formulation would be lower in cost because of the lower
concentrations of the antifungal and keratolytic agents. Additionally, such
formulation would reduce the unwanted side effects caused by high
concentrations of the antifungal and keratolytic agents and yet be suitable
for
treatment of fungal infections of the nail and surrounding tissues.
CA 02341814 2001-03-22
x
SUMMARY OF THE INVENTION
The present invention provides a pharmaceutical sustained release
preparation in a varnish or spray form for local treatment of the nail and
surrounding tissues, where the active ingredient is an antifungal agent, a
keratolytic agent, or preferably a combination of an antifungal and a
keratolytic
agent. The composition may further comprise an antibacterial, an antiviral, an
antipsoriatic agent or combinations thereof.
In a first embodiment the present invention provides a sustained release
nail varnish composition comprising:
(a) a pharmaceutically effective agent;
(b) a humectant;
(c) water;
(d) less than about 7.5% (w/w) based on the total weight of the composition,
of a polymeric film-forming agent;
(e) at least one additional excipient; and
(f) a solvent system including at least one volatile solvent.
In a second embodiment the present invention provides a sustained
release nail varnish composition comprising:
CA 02341814 2001-03-22
9
(a) an antifungal agent;
(b) a keratolytic agent;
(c) a humectant;
(d) water;
(e) a polymeric film-forming agent;
(f) at least one additional excipient; and
(g) a solvent system including at least one volatile solvent.
In a preferred embodiment the pharmaceutically effective agent is
selected from the group consisting of an antifungal agent, a keratolytic
agent,
to and mixtures thereof.
In a preferred embodiment the antifungal agent is selected from the
group consisting of amphothericin B, butefanine, butoconazole, carbol-fuchsin,
ciclopirox, clioquinol, clotrimazole, econazole, gentian violet, ketoconazole,
miconazole, naftifine, nystatin, oxiconazole, sodium thiosulfate, terbinafine,
terconazole, tolnaftate, undecylenic acid, therapeutically acceptable salts
thereof, derivatives thereof, and mixtures thereof.
In a preferred embodiment the concentration of the antifungal agent in
the varnish solution is less than about 1% (w/w).
In a preferred embodiment the antifungal agent is present in
CA 02341814 2001-03-22
concentration of less than about 5% (w/w) based on the weight of the
non-volatile components.
In a preferred embodiment the keratolytic agent is selected from the
group consisting of urea, sulfur, salicylic acid, podophyllum resin, and
mixtures thereof.
In a preferred embodiment the concentration of the keratolytic agent in
the varnish solution is less than about 1% (w/w).
In a preferred embodiment the keratolytic agent is present in
concentration of from about 0.05% to about 5% (w/w), based on the weight of
io the non-volatile components.
In a preferred embodiment the pharmaceutically effective agent further
comprises an antibacterial, an antiviral, an antipsoriatic agent, or mixtures
thereof.
In a preferred embodiment the antibacterial agent is selected from the
group consisting of bacitracin, clindamycin, erythromycin, gentamicin,
mupirocin, neomycin, tetracyclines, polymyxin B, benzalkonium chloride,
boric acid, hexachlorophene, iodine, iodoquinol, mafenide, mercury
ammoniated, metronidazole, nitrofurazone, selenium sulfide, silver
sulfadiazine, salts thereof, derivatives thereof, and mixtures thereof.
CA 02341814 2001-03-22
11
In a preferred embodiment the concentration of the antibacterial agent in
the varnish solution is from about 0.01% to about 1% (w/w).
In a preferred embodiment the antibacterial agent is present in
concentration of from about 0.05% to about 5% (w/w), based on the weight of
the non-volatile components.
In a preferred embodiment the antiviral agent is selected from the group
consisting of acyclovir, amantadine, cidofovir, famciclovir, foscamet,
ganciclovir, palivizumab, penciclovir, ribavirin, rimantadine, valcyclovir,
salts
thereof, derivatives thereof, and mixtures thereof.
In a preferred embodiment the concentration of the antiviral agent in the
varnish solution is from about 0.08% to about 0.8% (w/w).
In a preferred embodiment the antiviral agent is present in concentration
of from about 0.8% to about 8% (w/w), based on the weight of the non-volatile
components.
In a preferred embodiment the antipsoriatic agent is selected from the
group consisting of alclometasone, amcinonide, betamethasone, clobetasol,
clocortolone, desonide, desoximetasone, diflorasone, fluocinolone,
fluocinonide, flurandrenolide, halcinonide, hydrocortisone, mometasone,
prednicarbate and triamcinolone, salts thereof, derivatives thereof, and
mixtures
CA 02341814 2001-03-22
l~
thereof.
In a preferred embodiment the concentration of the antipsoriatic agent in
the varnish solution is from about 0.02% to about 2% (w/w).
In a preferred embodiment the antipsoriatic agent is present in
concentration of from about 0.1 % to about 10% (w/w), based on the weight of
the non-volatile components.
In a preferred embodiment the humectant is selected from the group
consisting of glycerol, sorbitol, and mixtures thereof.
In a preferred embodiment the concentration of the humectant in the
varnish solution is from about 3% to about 15% (w/w).
In a preferred embodiment the humectant is present in concentration of
from about 5% to about 35% (w/w), based on the weight of the non-volatile
components.
In a preferred embodiment the water concentration in the varnish
solution is less than about 5% (w/w).
In a preferred embodiment the concentration of the water in the film is
from about 0.4% to about 25% (w/w).
In a preferred embodiment the polymeric film-forming agent is selected
from the group consisting of hydrophobic (water insoluble) polymers.
CA 02341814 2001-03-22
, . 1 )
In a preferred embodiment the hydrophobic (water insoluble) polymer is
selected from the group consisting of hydrophobic cellulose derivatives,
hydrophobic methacrylic polymers, cellulose acetate phthalate, shellac,
derivatives thereof, and mixtures thereof.
In a preferred embodiment the hydrophobic cellulose derivative is
selected from the group consisting of ethyl cellulose of any acceptable
molecular weight.
In a preferred embodiment the hydrophobic methacrylic polymer is
selected from the group consisting of methacrylic acid copolymer type B
(USP/NF), methacrylic acid copolymer type C (USP/NF), ammonio
methacrylate copolymer type B (USP/NF) and ammonio methacrylate
copolymer type A(USP/NF), derivatives thereof, and mixtures thereof.
In a preferred embodiment the hydrophobic methacrylic polymer is
selected from the group consisting of Eudragit S, Eudragit L, Eudragit RS, and
Eudragit RL manufactured by Rohm Pharma, but hydrophobic methacrylic
polymers from other sources can also be used.
In a preferred embodiment the concentration of the polymeric
film-forming agent in the varnish solution is less than about 7.5% (w/w).
In a preferred embodiment the polymeric film-forming agent is present
CA 02341814 2001-03-22
14
in concentration of from about 8% to about 35% (w/w), based on the weight of
the non-volatile components.
In a preferred embodiment the weight ratio of polymer to the antifungal
agent is in the range from about 1:0.01 to about 1:0.3.
In a preferred embodiment the weight ratio of polymer to the keratolytic
agent is in the range from about 1:0.01 to about 1:1.
In a preferred embodiment the weight ratio of polymer to antibacterial
agent is in the range from about 1:0.01 to about 1:0.3.
In a preferred embodiment the weight ratio of polymer to antiviral agent
to is in the range from about 1:0.02 to about 1:0.2.
In a preferred embodiment the weight ratio of polymer to antipsoriatic
agent is in the range from about 1:0.006 to about 1:0.15.
In a preferred embodiment the at least one additional excipient is
selected from a group consisting of plasticizers.
In a preferred embodiment the plasticizer is selected from the group
consisting of dibutyl sebacate, diethyl phthalate, lanolin alcohols, mineral
oil,
petrolatum, polyethylene glycol, propylene glycol, triacetin, triethyl
citrate, and
mixtures thereof.
In a preferred embodiment the concentration of the plasticizer in the
CA 02341814 2001-03-22
l~
varnish solution is from about 0.1 '/o to about 2% (w/w).
In a preferred embodiment the plasticizer is present in concentration of
from about 0.5% to about 10% (w/w), based on the weight of the non-volatile
components.
In a preferred embodiment the weight ratio of the plasticizer to the
polymer is in the range from about 0.04:1 to about 0.3:1.
In a preferred embodiment the volatile solvent is selected from the group
consisting of an alcohol, a ketone, and mixtures thereof.
In a preferred embodiment the alcohol is selected from the group
to consisting of ethanol, isopropyl alcohol, methanol and mixtures thereof.
In a preferred embodiment the ketone is acetone.
In a preferred embodiment the volatile solvent is a mixture of acetone
and isopropyl alcohol.
In a preferred embodiment the volatile solvent is present in an amount of
from about 60% to about 90% (w/w), relative to the total weight of the
composition.
In a preferred embodiment the volumetric ratio of acetone to isopropyl
alcohol is in the range from about 1:4 to about 4:1.
In a preferred embodiment the solvent system further includes at least
CA 02341814 2001-03-22
16
one non-volatile solvent selected from the group consisting of benzyl alcohol,
benzyl benzoate, corn oil, cottonseed oil, ethyl oleate, glycerin, glycofural,
isopropyl myristate, isopropyl palmitate, mineral oil, peanut oil,
polyethylene
glycol, propylene glycol, propylene carbonate, sesame oil, soybean oil, water,
and mixtures thereof. .
In a preferred embodiment the composition may further comprise
preservatives, antioxidants, surfactants and coloring agents.
In a third embodiment the present invention provides a method of
preparing a sustained release varnish or spray formulation for treating the
nail
and surrounding tissues, comprising the steps of (a) preparing a solution
including at least one volatile solvent; (b) adding water to the solution
prepared in (a); (c) dissolving the pharmaceutically effective agents, and
excipients in the solution prepared in (b); (d) adding the humectant to the
solution prepared in (c) when the formulation ingredients are completely
dissolved; and (e) dissolving the polymeric film-forming agents in the
solution
prepared in (d).
Defmitions
By "varnish solution" is meant the total composition before evaporation
CA 02341814 2001-03-22
17
of the volatile components.
By "film" is meant the non-volatile components, which are remained
after evaporation of the volatile components of the varnish solution.
By "concentration or amount relative to the total weight of the
composition" is meant concentration in the varnish solution, before
application
to the nail or before evaporation of the volatile components.
By "concentration or amount based on the weight of the non-volatile
components" is meant concentration based on the weight of the components
remaining after evaporation of the volatile components (i.e. concentration in
to the film).
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The aim of this invention was to develop a sustained release delivery
system for antifungal agents achieving high penetration through the nail by
combining the antifungal agent with a keratolytic agent and a humectant.
The present invention provides a topical, sustained release
pharmaceutical preparation in a varnish or spray form for treating the nail
and
surrounding tissues, where the active ingredient is an anti-fungal agent, a
CA 02341814 2001-03-22
18
keratolytic agent, or preferably a combination of an antifungal and a
keratolytic
agent. The composition may further comprise an antibacterial, an antiviral, an
antipsoriatic agent or combinations thereof.
The composition features an effective quantity of at least one antifungal
agent, an effective quantity of at least one keratolytic agent, a humectant,
water, polymers, optionally at least one additional pharmaceutical excipient
and
finally a solvent medium. The additional excipients include plasticizers. The
composition may further comprise an effective quantity of at least one
antibacterial, antiviral, antipsoriatic agent or combinations thereof.
The delivery system is in the form of a solution or spray for
self-application by the patient. After application of the solution to the nail
surface, the solvent evaporates and a film/coating is formed on the surface.
The
film/coating has the capacity to release the antifungal and keratolytic agents
in
therapeutic levels over a prolonged period of time.
The combination of an antifungal and keratolytic agent is advantageous
because it increases the penetration of the antifungal agent through the nail.
Because the amount of water in the nail is very low, it is essential to
achieve
relatively high concentrations of water in the film. The humectant is added to
the present invention in order to retain water in the film after the
evaporation of
CA 02341814 2001-03-22
19
the organic solvents. The film formed after evaporation of the volatile
solvents
contains the pharmaceutically effective agents, polymers, humectant, the water
entrapped by the humectant, and additional non-volatile excipients. The
presence of water in the film is of significant importance because it
maintains
the active agents in a saturated-reservoir solution, thus enabling the
solubilized
agents to be released in a controlled manner into the nail.
The combination of glycerol (humectant), water and low concentrations
of keratolytic and antifungal agents, used in the present invention, are
particularly advantageous. The water entrapped in the film by the glycerol
to hydrates the nail and enables low concentrations of the keratolytic agent
to be
used in order to increase the permeability of the nail. Consequently lower
concentrations of the antifungal agent will be adequate in order to diffiuse
through the nail and provide the desired pharmacological action. Such a
combination would reduce the unwanted side effects caused by high keratolytic
agent and antifungal agent concentrations. An additional advantage of the use
of low keratolytic agent and antifungal agent concentrations is the reduction
of
the product price.
The antifungal agents are preferably amphothericin B, butefanine,
butoconazole, carbol-fuchsin, ciclopirox, clioquinol, clotrimazole, econazole,
CA 02341814 2001-03-22
gentian violet, ketoconazole, miconazole, naftifine, nystatin, oxiconazole,
sodium thiosulfate, terbinafine, terconazole, tolnaftate, undecylenic acid,
therapeutically acceptable salts thereof, derivatives thereof, and mixtures
thereof, more preferably clotrimazole and miconazole nitrate, most preferably
5 miconazole nitrate. Preferably the concentration of the antifungal agents in
the
varnish solution is less than about 1% (w/w) and most preferably 0.3-0.9%
(w/w).
Preferably the concentration of the antifungal agents based on the
weight of the non-volatile components is less than about 5% (w/w) and most
10 preferably 0.3-4.7% (w/w).
The keratolytic agents are added to the present invention in order to
increase the permeability of and penetration into the nail.
The keratolytic agents are preferably urea, sulfur, salicylic acid,
podophyllum resin, and mixtures thereof, most preferably urea. Preferably the
15 concentration of the keratolytic agents in the varnish solution is less
than about
1%(w/w), and most preferably 0.3-0.9% (w/w). Preferably the concentration of
the keratolytic agent based on the weight of the non-volatile components is in
the range from about 0.05% to about 5% (w/w).
The antibacterial agents are preferably bacitracin, clindamycin,
CA 02341814 2001-03-22
21
erythromycin, gentamicin, mupirocin, neomycin, tetracyclines, polymyxin B,
benzalkonium chloride, boric acid, hexachlorophene, iodine, iodoquinol,
mafenide, mercury anunoniated, metronidazole, nitrofurazone, selenium
sulfide, silver sulfadiazine, salts thereof, derivatives thereof, and mixtures
thereof. Preferably the concentration of the antibacterial agents in the
varnish
solution is in the range from about 0.01% to about 1% (w/w), and most
preferably 0.2-0.8% (w/w). Preferably the concentration of the antibacterial
agents based on the weight of the non-volatile components is in the range from
about 0.05% to about 5% (w/w) and most preferably 1.5-4.5% (w/w).
The antiviral agents are preferably acyclovir, amantadine, cidofovir,
famciclovir, foscarnet, ganciclovir, palivizumab, penciclovir, ribavirin,
rimantadine, valcyclovir, salts thereof, derivatives thereof, and mixtures
thereof. Preferably the concentration of the antiviral agents in the varnish
solution is in the range from about 0.08% to about 0.8% (w/w) and most
preferably 0.2-0.6% (w/w). Preferably the concentration of the antiviral
agents
based on the weight of the non-volatile components is in the range from about
0.8% to about 8% (w/w) and most preferably 2-6% (w/w).
The antipsoriatic agents are preferably alclometasone, amcinonide,
betamethasone, clobetasol, clocortolone, desonide, desoximetasone,
CA 02341814 2001-03-22
22
diflorasone, fluocinolone, fluocinonide, flurandrenolide, halcinonide,
hydrocortisone, mometasone, prednicarbate, triamcinolone, salts thereof,
derivetives thereof, and mixtures thereof. Preferably the concentration of the
antipsoriatic agents in the varnish solution is in the range from about 0.02%
to
about 2% (w/w) and most preferably 0.2-1.5% (w/w). Preferably the
concentration of the antipsoriatic agents based on the weight of the non-
volatile
components is in the range from about 0.1% to about 10% (w/w) and most
preferably 1-7.5% (w/w).
Since the water content of the nail is very low it is important to achieve
relatively high concentrations of water in the delivery system. The humectant
is added to the varnish solution in order to hold the water in the film after
evaporation of the organic solvents. The presence of water in the film
hydrates
the nail so that the active agents can be delivered into the deeper layers of
the
nail. The humectant is preferably glycerol, sorbitol, and mixtures thereof,
most
preferably glycerol. Preferably the concentration of the humectant in the
varnish solution is in the range from about 3% to about 15% (w/w), and most
preferably 4-10% (w/w).
Preferably the concentration of the humectant based on the weight of the
non-volatile components is in the range from about 5% to about 35% (w/w),
CA 02341814 2001-03-22
23
and most preferably 10-30% (w/w).
Although glycerol can serve at lower concentrations (less than 2% w/w
based on the total weight of the composition) as a plasticizer, at this lower
concentration range glycerol is not efficient as a humectant and therefore
higher concentrations (above 3% w/w) of glycerol are required in order to be
effective as a humectant.
Preferably the water concentration in the varnish solution is less than
about 5% (w/w), more preferably 0.5-4.5% (w/w) and most preferably 1-4.5%
(w/w). Preferably the concentration of the water in the film is in the range
from
to about 0.4% to about 25% (w/w), more preferably 0.8-20% (w/w), and most
preferably 2-18% (w/w).
The delayed release polymeric film-forming agents are preferably
hydrophobic (water insoluble) polymers. The hydrophobic (water insoluble)
polymers are preferably hydrophobic cellulose derivatives, hydrophobic
methacrylic polymers, cellulose acetate phthalate, shellac, derivatives
thereof
and mixtures thereo~ The hydrophobic cellulose derivatives are preferably
ethyl cellulose of any acceptable molecular weight.
The hydrophobic methacrylic polymers are preferably methacrylic acid
copolymer type B (USP/NF), methacrylic acid copolymer type C(USP/NF),
CA 02341814 2001-03-22
24
ammonio methacrylate copolymer type B (USP/NF) and ammonio
methacrylate copolymer type A(USP/NF), derivatives thereof, and mixtures
thereof. The hydrophobic methacrylic polymers are preferably Eudragit S,
Eudragit L, Eudragit RS, and Eudragit RL manufactured by Rohm Pharma, but
hydrophobic methacrylic polymers from other sources can also be used. The
polymers provide a uniform film, retard the release rate of the drugs
(agents),
and can be mixed in regulated amounts to attain the desired drug release
characteristics.
Preferably the concentration of the polymeric film-forming agent in the
to varnish solution is less than about 7.5% (w/w). Preferably the
concentration of
the polymeric film-forming agent based on the total weight of the non-volatile
components is in the range from about 8% to about 35% (w/w), more
preferably 18-30% (w/w) and most preferably 23-27% (w/w).
Preferably the weight ratio of polymer to the antifungal agent is in the
range from about 1:0.01 to about 1:0.3 and most preferably is in the range
from
about 1:0.06 to about 1:0.25.
Preferably the weight ratio of polymer to the keratolytic agent is in the
range from about 1:0.01 to about 1:1 and most preferably is in the range from
about 1:0.05 to about 1:1
CA 02341814 2001-03-22
Preferably the weight ratio of polymer to antibacterial agent is in the
range from about 1:0.01 to about 1:0.3 and most preferably is in the range
from
about 1:0.05 to about 1:0.25.
Preferably the weight ratio of polymer to antiviral agent is in the range
5 from about 1:0.02 to about 1:0.2 and most preferably is in the range from
about
1:0.05 to about 1:0.2.
Preferably the weight ratio of polymer to antipsoriatic agent is in the
range from about 1:0.006 to about 1:0.15 , and most preferably is in the range
from about 1:0.01 to about 1:0.15.
10 Plasticizers are added to the varnish solution in order to enhance the
plasticity of the film formed and to modify the sustained release
characteristics
of the polymer. The plasticizer is preferably dibutyl sebacate, diethyl
phthalate,
lanolin alcohols, mineral oil, petrolatum, polyethylene glycol, propylene
glycol,
triacetin, triethyl citrate, or mixtures thereof, and most preferably
polyethylene
15 glycol with molecular weight of 300-6000.
Preferably the concentration of the plasticizer in the varnish solution is
in the range from about 0.1% to about 2% (w/w), more preferably 0.2-1%
(w/w), and most preferably 0.4-0.8% (w/w). Preferably the concentration of the
plasticizer based on the total weight of the non-volatile components is in the
CA 02341814 2001-03-22
26
range from about 0.5% to about 10% (w/w), more preferably 1-5% (w/w), and
most preferably 2-3% (w/w).
Preferably, the weight ratio of the plasticizer to the polymer is in the
range from about 0.04:1 to about 0.3:1, and most preferably, the weight ratio
of
the plasticizer to polymer is in the range from about 0.05:1 to about 0.2:1.
Preferably the volatile solvent is selected from the group consisting of
an alcohol, a ketone, and mixtures thereof.
The alcohol is preferably ethanol, isopropyl alcohol, methanol and
mixtures thereof. The ketone is preferably acetone.
Preferably the volatile solvent is a mixture of acetone and isopropyl
alcohol.
Preferably the volatile solvent is present in an amount of from about
60% to about 90% (w/w), and most preferably from about 70% to about 85%
(w/w) relative to the total weight of the composition.
Preferably the volumetric ratio of acetone to isopropyl alcohol is in the
range from about 1:4 to about 4:1 and most preferably from about 1:3 to about
3:1.
Preferably the solvent system further includes at least one non-volatile
solvent.
CA 02341814 2001-03-22
27
The at least one non-volatile solvent is preferably benzyl alcohol, benzyl
benzoate, corn oil, cottonseed oil, ethyl oleate, glycerin, glycofural,
isopropyl
myristate, isopropyl palmitate, mineral oil, peanut oil, polyethylene glycol,
propylene glycol, propylene carbonate, sesame oil, soybean oil, water, and
mixtures thereof. .
Optional ingredients include at least one additive chosen from among
the group consisting of preservatives, antioxidants, surfactants and coloring
agents which are well known in the art.
The preservative is preferably benzoic acid, benzyl alcohol, bronopol,
to butyl paraben, chlorbutanol, chlorocresol, cresol, ethyl paraben, methyl
paraben, phenol, propyl paraben, sodium benzoate, sodium propionate, sorbic
acid, or mixtures thereof
The antioxidant is preferably alpha tocopherol, ascorbic acid, ascorbyl
palmitate, butylated hydroxyanisole, butylated hydroxytoluene, fumaric acid,
malic acid, propyl gallate, sodium ascorbate, sodium metabisulfite, or
mixtures
thereof.
The surfactant is preferably cetrimide, sodium lauryl sulfate, docusate
sodium, glyceryl monooleate, polysorbates, sorbitan esters, or mixtures
thereof.
The coloring agent is preferably amaranth, brilliant blue, caratenoids,
CA 02341814 2001-03-22
28
carmoisine, curcumin, eosine, erythrosine, fluorescein, rhodoxantin,
tetrazine,
or mixtures thereof.
The composition prepared according to the present invention may
advantageously be presented in the form of varnish or spray.
For a better understanding of the object of the invention, several
examples of this composition are described; these are intended as purely
illustrative examples without any intention of being limiting. It is to be
understood that the invention is not limited in its application to the details
of
construction and the arrangement of the components set forth in the following
to description. The invention includes other embodiments and can be practiced
or
implemented in various ways. It is also to be understood that the phraseology
and terminology employed herein is for the purpose of description only and
should not be regarded as litniting.
EXAMPLES OF THE FORMULATIONS OF THE PRESENT INVENTION
Example I
The formulations of the present invention were all prepared according to the
general procedure which is described below (Preparation of Varnish).
CA 02341814 2005-12-05
29
Antifungal nail varnish sustained release formulations (guantities are in %
w/w
Formulation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
No
Urea 0.7 0.7 0.7 0.7 0.8 0.8 0.8 0.7 0.7 0.7 0.7 0.7 0.9 0.9 0.8
Clotrimazole 0.9 0.8 0.4 0.9 0.8
Miconazole 0.8 0.8 0.8 0.8 0.8 0.8 0.9 0.8 0.98 0.4
nitrate
Ethyl 0:8 0.8 3.4 4.2 4.3
Cellulose -
Eudragit S 7-3 6.5 6.2 5.0 7.3 7.4 7.3 7.3 7.4 7.3 7.3
0.9 7.3
Eudragit RS
Water 4.0 4.1 4.1 4.1 4.3 4.2 4.4 4.1 4.1 4.1 4.0 4.0 4.0 4.1 4.1
Acetoue 61.3 61.8 61.5 62.3 63.9 63.3 65.6 61.3 61.2 61.5 61.2 61.2 61.5 61.0
61.1
Liopropyl 20.4 20.6 20.5 20.8 213 21.1 211 20.4 20.4 20.5 20.4 20.4 20.5 20.3
20.4
alcohol
PEG 400 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
Glycerol 4.9 5.0 4.9 5.0 5.1 5.1 5.2 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9
General procedure for the varnish preparation
A mixture of acetone and isopropyl alcohol was prepared. Water was added to
the organic mixture and then urea was dissolved in the solution. PEG and the
antifungal agent (miconazole nitrate) were added and dissolved in the
solution.
When the antifungal agent was completely dissolved, the humectant was added
1 o to the solution. Thereafter the polymer was added to the solution. The
solution
was brought to the final weight using the organic mixture prepared in the
first
CA 02341814 2001-03-22
step. All the steps of the varnish preparation were performed while
continuously stirring the solution.
Film preparation
5 The films were cast from the varnish solutions onto glass surfaces (petri
dishes). The solvent was allowed to evaporate for 24 h and the fihn was
removed from the surface. Films of 100x10' cm in thickness were prepared
and used for testing of (1) water residue in the film (2) dissolution rate of
the
active agents from the film and (3) sustained antifungal activity in vitro.
15
CA 02341814 2001-03-22
31
Example 2
Determination of the water residue in the films
All the films were tested using the Karl Fisher method to determine the water
content.
Formulation No.* Water in dry film, %(w/w)
1 12
1** 5
6 13
6** 4
7 13
7** 3
* The formulation No. is related to the table in Example 1
**without glycerol
to These results show that the humectant is able to hold the water in the dry
film.
CA 02341814 2001-03-22
32
Example 3
Dissolution rates of the active agents (iniconazole nitrate and urea)
Fihns were cut to a circular form, 2.54 cm2 in area, and were weighed
accurately. Film thickness was measured with a micrometer. The membranes
were attached to a specially designed dissolution basket in which only one
surface of the membrane was exposed to the dissolution medium. 150 ml of 1%
sodium lauryl sulfate solution served as the dissolution medium. The
dissolution rates were measured in a Van-Kel (VK 7000) dissolution test
apparatus at 32 C and 100 rpm rotating speed.
Aliquots were withdrawn at various times and replaced by fresh solvent,
with corrections being applied in the calculations. The amount of drug
released
was detecmined spectrophotometrically at 230 nm for miconazole and 564 nm
(color reaction) for urea.
The dissolution rates of miconazole nitrate and urea are presented in the
following tables:
CA 02341814 2001-03-22
33
Dissolution rates of miconazole nitrate from the formulations described in
example 1
Amount drug released (%)
Formulation
60 min 120 min 240 min 480 min 1440 min
1 7.5 21.2 37.8 50.2 96.1
6 6.5 11.8 20.8 30.5 61.2
7 5.1 8.4 14.2 20.6 52.4
14 7.0 16.0 21.8 28.9 70.1
Dissolution rates of urea from the formulations described in example 1
Amount drug released (%)
Formulation
60 min 120 min 240 min 480 min 1440 min
1 15.8 33.4 59.7 96.2
6 10.2 26.1 42.5 65.0 99.8
7 8.6 19.1 38.9 49.2 95.1
14 11.2 24.0 46.2 61.0 98.6
The results show that both miconazole nitrate and urea are released from
the films in a controlled manner. The release of urea is higher than
miconazole
nitrate, this can be explained by the higher solubility and lower molecular
CA 02341814 2001-03-22
34
weight of urea, compared to miconazole nitrate. The faster release of urea
compared to miconazole nitrate is advantageous since higher concentrations of
urea increases the permeability of the nail thereby enabling better
penetration
of the antifungal agent (miconazole) into deeper layers of the nail.
Example 4
Sustained release activity of clotrimazole and miconazole nitrate in vitro
A strain of Saccharomyces cerevisiea was used in this study. A 1:10
to dilution of a stock suspension of the above organism was mixed with
mycological culture medium and poured into petri dishes. 5 mm diameter discs
of the film (Formulation No 1, 6, 7, 14) containing clotrimazole or miconazole
nitrate were placed on the hardened medium and incubated for 24 h at 37 C.
Thereafter the films were transferred to another set of petri dishes
containing
the same medium plus Saccharomyces cerevisiea.
Inhibition zones were recorded after incubation period of 24 hours. All
samples were tested in triplicate. The mean inhibition zone sizes are
summarized in the following table.
CA 02341814 2001-03-22
Inhibition zones of S. cerevisiea growth by sustained release films containing
miconazole nitrate (formulation No 1,6,7) and clotrimazole (formulation No
14).
Inhibition Zone (mm)
Time Formulation No
1 6 7 14
24 hrs 30.67 28.77 28.37 28.64
48 hrs 24.29 20.60 24.95 25.83
72 hrs 21.57 21.72 24.03 21.39
96 hrs 20.59 21.09 24.28 21.11
144 hrs 18.18 19.52 22.94 20.01
5 The measurements of the inhibition zone were discontinued after 6
days. There was no inhibition of Saccharomyces growth in control samples of
the film containing no antifungal agent. The results reveal that the
antifungal
agent embedded in the film is pharmacologically active and is able to inhibit
the growth of Saccharomyces cerevisiea strain for a prolonged period of time.
io
Examples of using the formulations
The compositions of the present invention may be applied to the infected
nail and surrounding tissues once a day up to once a week.
CA 02341814 2001-03-22
36
It is understood that the precise concentrations and duration of treatment
is a function of the tissue being treated. It is to be noted that
concentrations
may also vary with the age and condition of the individual treated. It is to
be
further understood that for any particular subject, the frequency of
application
should be adjusted over time according to the individual need and professional
judgment of the physician or person administering or supervising the
administration of the formulations.
It will be appreciated that the above descriptions are intended only to
serve as examples, and that many other embodiments are possible within the
to spirit and the scope of the present invention.
